Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority

Lorenc Karol, Kozioł Magdalena, Sobek Alicja, Pawlicki Mateusz, Łopuszyńska Anna, Misztal Zofia, Lewicki Marcin, Smoleń Agata. Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority. Journal of Education, Health and Sport. 2019;9(5):81-88. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.2667284

http://ojs.ukw.edu.pl/index.php/johs/article/view/6881

https://pbn.nauka.gov.pl/sedno-webapp/works/912614

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017).

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Authors 2019;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 12.04.2019. Revised: 25.04.2019. Accepted: 04.05.2019.

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority

Karol Lorenc^a, Magdalena Kozioł^a, Alicja Sobek^a, Mateusz Pawlicki^a, Anna Łopuszyńska^a, Zofia Misztal^b, Marcin Lewicki^c, Agata Smoleń^c

^aStudent Scientific Association at Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, ul. Radziwiłłowska 11, Lublin 20-080, Poland; lorenckarol2@gmail.com; 0000-0002-6414-5984; magdalena.koziol@icloud.com; 0000-0002-8671-5968; ala01p@wp.pl; 0000-0001-5563-9344; pawlak32@gmail.com; 0000-0001-8318-6573; lopuszynskaania@gmail.com; 0000-0001-5133-4180;

^bStudent Scientific Association at Department of Family Medicine, Medical University of Lodz, ul. Narutowicza 60, Lodz 90-136, Poland; zosia.misztal6@gmail.com; 0000-0003-2317-9667

^cDepartment of Epidemiology and Clinical Research Methodology of the Medical

University of Lublin, ul. Radziwiłłowska 11, Lublin 20-080, Poland; lewicki-marcin@wp.pl; 0000-0003-1906-9326; agatasmolen@umlub.pl; 0000-0003-0764-6667;

ABSTRACT:

Increase in the incidence of multidrug-resistant Gram-negative bacterial strains pose
a significant threat to healthcare system worldwide. New antibiotics are necessary to combat particularly resitant pathogens. WHO’s global priority pathogens list was published in 2017 to promote research and development of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial agents. Acinetobacter baumannii, Pseudomonas aeruginosa and carbapenem-resistant, third-generation cephalosporin-resistant Enterobacteriaceae were classified as highest priority pathogens requiring a new antibiotic treatment options. Cefiderocol is a novel parenteral siderophore cephalosporin that shows efficacy against listed Gram-negative bacteria. The results of the presented studies showed that cefiderocol has a strong antimicrobial effect against problematic strains that produce carbapenemases, such as KPC (K. pneumoniae carbapenemase) and B-class
metallo-β-lactamases, including NDM-1 (New Delhi metallo-β-lactamase), as well as the ESBL-producing strains. In addition, it does not require the use of the β-lactamase inhibitor. The new agent demonstrates a favorable side effect profile. There is an urgent need to develop new antibiotics. Cefiderocol is a new antibiotic that has a potential to effectively combat particularly resistant bacteries such as carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, as well as carbapenem and 3rd generation cephalosporin-resistant Enterobacteriaceae.

Key words: Cefiderocol; cephalosporin; antibiotic resistance